Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease.

Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as the most common cause of chronic liver disease worldwide. It has been shown that NAFLD in adults is associated with increased risk of coronary heart disease (CHD). Because of the limitations of liver biopsy, noninvasive scoring indexes such as the NAFLD fibrosis score (NFS) were developed. The Framingham risk score (FRS) provides an estimate of CHD risk. In our study we aimed to investigate whether the severity of liver fibrosis estimated with the NFS is associated with a higher risk of CHD among individuals with ultrasonography-diagnosed NAFLD.
A total of 155 patients and controls (81 patients with NAFLD and 74 controls) with ages ranging from 18 to 70 years were enrolled in this cross-sectional prospective study. Demographic, anthropometric, clinical, and laboratory data were obtained from each individual. The NAFLD patients were divided into subgroups on the basis of the severity of fatty liver. The FRS and NFS were adopted to predict the risk of CHD and the severity of hepatic fibrosis.
In our study, we found that the FRS was higher in NAFLD patients than in controls (P<0.05). According to the FRS category, NFSs were higher in the intermediate/high probability CHD risk group in NAFLD (P<0.05). In multiple models, only age, sex, cholesterol, and HDL were independently associated with intermediate/high CHD risk (P<0.05). We also found a positive correlation between the NFS and the FRS (r=0.373, P<0.001). The optimum NFS cutoff point for identifying intermediate/high CHD risk in NAFLD patients was -2.1284, with a sensitivity and specificity of 95.20 and 48.30%, respectively. The predictive performance of the NFS in the determination of intermediate/high CHD risk in NAFLD patients was found to be 72% based on the area under the curve value.
The FRS is associated with the NFS in NAFLD. The assessment of liver fibrosis may be useful for the risk stratification of CHD in the absence of liver biopsy in clinical practice.
AuthorsSerkan Dogan, Mehmet Celikbilek, Yunus K Yilmaz, Savas Sarikaya, Gokmen Zararsiz, Halil I Serin, Elif Borekci, Lütfi Akyol, Ilyas Pirti, Sena E Davarci
JournalEuropean journal of gastroenterology & hepatology (Eur J Gastroenterol Hepatol) Vol. 27 Issue 3 Pg. 298-304 (Mar 2015) ISSN: 1473-5687 [Electronic] England
PMID25629574 (Publication Type: Journal Article)
  • Adolescent
  • Adult
  • Aged
  • Case-Control Studies
  • Coronary Disease (etiology)
  • Cross-Sectional Studies
  • Female
  • Humans
  • Liver Cirrhosis (complications, ultrasonography)
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease (complications, ultrasonography)
  • ROC Curve
  • Risk Assessment (methods)
  • Severity of Illness Index
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: